A study by Hu et al. showed that lncRNA ROR1‐AS1 overexpression promotes tumour growth and decreases sensitivity to ibrutinib and dexamethasone in patients with MCL, highlighting its role as a marker for response to therapy.60 Here, ROR1 is linked to neoplasm.